COMMUNIQUÉS West-GlobeNewswire

Viracta and Salubris Announce Equity Financing and Partnership to Bring Novel Treatment for Viral-Associated Cancers to China
04/12/2018
SAN DIEGO and SHENZHEN, China, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Shenzhen Salubris Pharmaceuticals Co. Ltd. (Salubris, SZSE: 002294) and Viracta Therapeutics, Inc. announced the initial closing of a financing, with [...]
Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies
04/12/2018
– Early Signs of Durable Response Across Patients with Relapsed/Refractory PTCL – – 50 Percent Complete Response Rate Observed in Patients with AITL – – Rapid and Significant Reduction in Itching Among Patients with [...]
Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting
04/12/2018
P-BCMA-101 showed a 100% ORR with patients achieving rapid and deep responses with no CRS or neurotoxicity observed at the planned Phase 2 dose SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a [...]
Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting
04/12/2018
Moffitt Cancer Center collaborators described next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases exhaustion Memorial Sloan Kettering collaborators [...]
Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia
04/12/2018
82 percent of Patients Achieved a Complete Remission when Lymphodepletion Regimen Included an anti-CD52 Monoclonal Antibody (mAb) Safety Profile of UCART19 Appears Manageable with No Evidence of Moderate or Severe Graft [...]
Driven Inc. to Present at the 11th Annual LD Micro Main Event
04/12/2018
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Driven Inc. (OTC: RBOS), a cannabis delivery service, announced today that they will be presenting at the 11th Annual LD Micro Main Event. The conference is being held on [...]
REVA Announces First Implant of the Fantom Encore Bioresorbable Scaffold in Italy
04/12/2018
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” Or The “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the first implant of its recently [...]
Phase 1 Expansion Cohort Oral Presentations for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, in Relapsed/Refractory Acute Myeloid Leukemia Presented at 60th ASH Annual Meeting
04/12/2018
Flotetuzumab demonstrated 29.4% complete response rate in evaluable primary refractory AML patients Translational studies suggest potential strategy for biomarker-based patient selection ROCKVILLE, Md., Dec. 03, 2018 ( [...]
National Rheumatology and Psoriasis Organizations Release Joint Guideline for Treating Psoriatic Arthritis
03/12/2018
Recommends Treat-to-Target Approach, First-Line Use of TNFi Biologics, and Smoking Cessation Atlanta, Dec. 03, 2018 (GLOBE NEWSWIRE) -- The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) [...]
Biocartis Group NV: Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla(TM) Oncotype DX Genomic Prostate Score® Test
03/12/2018
PRESS RELEASE: 3 December 2018, 22:30 CET/16:30 EST Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla(TM) Oncotype DX Genomic Prostate Score ® Test REDWOOD CITY, Calif., [...]
Osmotica Pharmaceuticals to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
03/12/2018
BRIDGEWATER, N.J., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison, Chief [...]
Geron Announces New Overall Survival Data from IMbark in Imetelstat-Treated Patients with Intermediate-2 or High-Risk Myelofibrosis and Relapsed/Refractory to Janus Kinase Inhibitor Therapy
03/12/2018
Data Reporting Median Overall Survival of 29.9 Months in High-Dose Arm Presented at the 60th American Society of Hematology Annual Meeting MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq [...]
Diversicare Completes Sale of Three Skilled Nursing Facilities in Kentucky
03/12/2018
BRENTWOOD, Tenn., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Diversicare Healthcare Services, Inc. (NASDAQ: DVCR), a premier provider of post-acute care services, today announced that effective December 1, 2018 the Company [...]
Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources
03/12/2018
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced [...]
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/12/2018
EMERYVILLE, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it [...]
Scholar Rock Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy
03/12/2018
CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth [...]
Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA®
03/12/2018
CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to [...]
Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030
03/12/2018
BOSTON, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today [...]
University Medical Centre Groningen chooses TAT-5000 of Exergen Medical as standard thermometer throughout hospital
03/12/2018
WATERTOWN, Mass. and GRONINGEN, The Netherlands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- University Medical Centre Groningen has decided to standardize on the TAT-5000 thermometer of Exergen Medical. The well-known university [...]

Pages